The ESRF cryo-electron microscope bears fruit in its first year

October 31, 2018

In November 2017, a Titan Krios cryo-electron microscope (cryo-EM) was inaugurated at the ESRF, the European Synchrotron, France. Data collected on this cryo-EM features in a Nature publication describing the activation cycle of a serotonin receptor, which is targeted by medication against chemotherapy- and radiotherapy-induced nausea.

"This publication is a true reward for us: the first one in less than a year from inauguration and we hope this kind of rewards will grow in number", explains Isai Kandiah, ESRF scientist who runs the facility. "It shows the revolution that cryo-EM is leading in structural biology", she adds. Thanks to cryo-EM, researchers can now freeze biomolecules, including membrane proteins of high medical importance, in several different conformations in action and visualise each of these to atomic resolution. Cryo-EM thus allows researchers to produce snapshots revealing the dynamics of proteins when they interact with other molecules, information that is crucial both for a basic understanding of life's chemistry and for the development of pharmaceuticals.

The research in Nature is a result of an international collaboration of scientists from the Institute of Structural biology (IBS-mixed research unit CEA-CNRS-University Grenoble Alps), the Institut Pasteur, the University of Lorraine (France), the University of Copenhagen (Denmark), the University of Illinois (US) and the biotech company Theranyx. The focus of the paper, featuring data from the ESRF cryo-EM, is the activation cycle of the 5-HT3 receptor, belonging to the family of serotonin receptors. These receptors are well known because they influence various biological and neurological processes such as anxiety, appetite, mood, nausea, sleep and thermoregulation, among others. Unlike the other serotonin receptors, which are G protein-coupled receptors, 5-HT3 is a neurotransmitter-gated ion channel and changes its conformation during activation. It is present in the brain, as well as in the enteric nervous system, the peripheral nervous system that drives the digestive tract.

5-HT3 is a target for drugs and pharmaceutical companies have studied it extensively. When patients undergo chemotherapy and/or radiotherapy, they often suffer from nausea and vomiting as side effects. In fact, the chemicals used in cancer treatment trigger an elevation of serotonin signalling, which in turn activates 5-HT3 to open its ion channel, which then causes nausea.

"The receptor has been widely studied due to its importance, but it hasn't been until recently, that we have accessed it at the atomic scale, thanks to cryo-electron microscopy, among other techniques", explains Hugues Nury, main author of the paper and CNRS scientist at the IBS.

The results published in Nature show the receptor 5-HT3 in four different conformations. Images of three of these were obtained at the Center for Cellular Imaging and Nano Analytics in Switzerland whilst the fourth, which finally allowed a full understanding of the activation mechanism of 5-HT3, was obtained at the ESRF. One of the conformations is inhibited thanks to the binding of anti-nausea and anti-vomiting drug widely used in chemotherapy. The images obtained of the receptor may therefore lead to the design of more efficient antinausea drugs for the treatment of patients undergoing therapy for cancers.

"These results contribute to our knowledge on how 5-HT3 receptors behave. They provide a framework for the myriad of mutations described in the literature: we can now look where they are, what are the motions in these zones, and sometimes why the mutations altered the receptor function. Now we also see the binding pockets in unprecedented details, which can help the development of future drugs", explains Hugues Nury.
Press contacts:

Scientists contact for the Nature publication

Hugues Nury,, +33 (0)4 57 42 85 93

Delphine CHENEVIER, Head of Communications, ESRF, +33 (0)6 07 16 18 79

CNRS Press office, +33 (0)1 44 96 51 51

About the ESRF:

The ESRF - the European Synchrotron, located in Grenoble, France -the world's most intense X-ray source. Founded in 1988, the ESRF celebrates its 30th anniversary, 30 years of excellence in science to decipher the secrets of matter. Each year, 10,000 scientists from all over the world come at the ESRF to image and study and studying the structure of matter in all fields of research, ranging from the chemistry and physics of materials to archaeology and cultural heritage, together with structural biology and medical applications, environmental sciences and information science and nanotechnologies.

European Synchrotron Radiation Facility

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to